Quanterix Corp 2026: Revenue $32.91M, EPS ($1.04) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Quanterix Corp reported Q2 2026 results with revenue of $32.91M, up 34.4% YoY, driven by the Akoya acquisition. Despite a net loss of ($48.93M) and diluted EPS of ($1.04), the company achieved $85M in annualized cost synergies from integration. Key progress includes CMS reimbursement for LucentAD Complete, a submitted 510(k) for an Alzheimer’s test, and plans for FDA IVD approval by 2027.
Quanterix Corp reported results for the quarter ended 2026, with revenue of $32.91M, a net loss of ($48.93M) and diluted loss per share of ($1.04), versus $24.48M, ($30.01M) and ($0.77) in the year-ago quarter, respectively.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $32.91M | $24.48M | 34.4% |
| Net income² | ($48.93M) | ($30.01M) | (63%) |
| Diluted EPS³ | ($1.04) | ($0.77) | (35.1%) |
¹ Reported as “Total revenues”. ² Reported as “Net loss”. ³ Reported as “loss per common share, basic and diluted”.
Business Highlights
- Revenue growth was driven by the acquisition of Akoya, helping total revenue rise 26% year-to-date to $69.3M despite softness in legacy Quanterix products.
- Akoya acquisition shifted the company’s channel and product mix, adding significant product and service revenue and increasing recurring consumables sales.
- Regulatory and commercial progress included a submitted 510(k) for an Alzheimer’s multi‑analyte blood test and LucentAD Complete receiving CMS reimbursement with payer coverage beginning.
- Operationally, the company completed Akoya integration, realizing approximately $85M of annualized cost synergies and consolidated systems; commercial leadership was reorganized and investments planned for sales, marketing and HD‑X upgrades to pursue FDA IVD approval in 2027.
Original SEC Filing: Quanterix Corp [ QTRX ] - 10-Q - Aug. 10, 2026